CJC-1295 without DAC 10mg
CJC-1295 Without DAC Peptide (RUO) | High Purity ≥99% | Research Grade
Product Specifications
| Specification | Details |
|---|---|
| Product Name | CJC-1295 Without DAC (Modified GRF 1-29) |
| Peptide Type | Synthetic 29-Amino Acid GHRH Analog — Tetrasubstituted |
| Also Known As | Mod GRF 1-29 / Modified GRF (1-29) / GHRH(1-29) Analog |
| CAS Number | 863288-34-0 |
| PubChem CID | 91976842 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | ~3,367.9 g/mol |
| Substitutions | Positions 2, 8, 15, 27 — DPP-IV Resistant Scaffold |
| Purity | ≥99% (RP-HPLC Verified) |
| Identity Confirmation | LC-MS Verified Per Batch |
| Endotoxin | <0.25 EU/mg (LAL Method) |
| Form | Lyophilized Powder |
| Solubility | Sterile or Bacteriostatic Water |
| Storage | 2–8°C lyophilized; −20°C reconstituted. Protected from light and moisture. |
What Is CJC-1295 Without DAC?
CJC-1295 Without DAC (Modified GRF 1-29) is a tetrasubstituted synthetic analog of endogenous human Growth Hormone-Releasing Hormone (GHRH) and is supplied exclusively for laboratory and preclinical research applications. Identified by PubChem CID 91976842, CJC-1295 Without DAC is widely referenced in peptide research literature for its characterized GHRH receptor binding profile, DPP-IV resistant scaffold, and reproducible pulsatile GH release dynamics in preclinical models.
The 29-amino acid sequence corresponds to the bioactive N-terminal fragment of GHRH, retaining full GHRH receptor (GHRHR) binding competence. Four stabilizing amino acid substitutions — at positions 2, 8, 15, and 27 — confer resistance to enzymatic degradation while preserving receptor selectivity, extending functional half-life from native GHRH’s approximately 7 minutes to approximately 30 minutes in research models.
The absence of the Drug Affinity Complex (DAC) is a defining research feature. Without the MPA albumin-binding conjugate present in the DAC variant, CJC-1295 Without DAC produces discrete, pulsatile GHRH receptor stimulation that more closely recapitulates endogenous hypothalamic GHRH secretion rhythms — making it the preferred GHRH analog for studies investigating GH pulse architecture, somatostatin interplay, and dual-pathway secretagogue synergy models.
Manufactured under controlled conditions and supplied in lyophilized form, this reagent is commonly utilized by qualified researchers requiring high-purity, batch-consistent materials for controlled experimental studies.
This product is clearly labeled and distributed strictly as a Research Use Only (RUO) material and is not approved for human or veterinary use.
Four Stabilizing Amino Acid Substitutions
| Position | Native GHRH Residue | Modified GRF Residue | Research Rationale |
|---|---|---|---|
| 2 | L-Ala | D-Ala | Blocks DPP-IV cleavage at the N-terminal Tyr-Ala bond |
| 8 | Gly | Aib / Gln | Prevents Asn deamidation and amide hydrolysis; enhances metabolic stability |
| 15 | Ala | Ala (modified) | Enhances GHRHR binding bioactivity and receptor engagement kinetics |
| 27 | Met / Ser | Leu | Prevents methionine oxidation during lyophilization and storage |
Experimental Research Applications
In scientific literature, CJC-1295 Without DAC has been investigated in a variety of experimental settings, including:
- GHRH receptor (GHRHR) signaling and cAMP-PKA somatotroph cascade research
- Pulsatile GH axis dynamics and somatostatin counterregulation studies
- GH-IGF-1 axis modulation and hepatic IGF-1 biosynthesis research
- DPP-IV resistance and peptide plasma stability investigations
- Dual-pathway GH secretagogue synergy models (GHRHR + GHS-R1a)
- Age-related GH axis decline and somatotroph responsiveness research
- Comparative GHRH analog scaffold studies
These studies are conducted exclusively within laboratory and preclinical environments and are intended for mechanistic and observational research purposes.
Purity and Quality Control
Each batch of CJC-1295 Without DAC undergoes analytical testing to ensure:
✔ ≥99% purity verified by RP-HPLC
✔ LC-MS identity and molecular weight confirmation per batch
✔ Endotoxin screening <0.25 EU/mg (LAL method)
✔ Batch-to-batch consistency
✔ Professional documentation and traceability
✔ Controlled manufacturing standards
✔ Reliable performance for repeatable research applications
High analytical purity and strict quality control procedures help provide researchers with confidence in the consistency and reliability of each batch.
Key Research Features
- Tetrasubstituted 29-amino acid GHRH analog
- DPP-IV resistant scaffold — four stabilizing substitutions
- ~30-minute half-life — pulsatile GH release profile
- No albumin-binding DAC conjugate — discrete pulse resolution
- ≥99% RP-HPLC-verified purity
- LC-MS sequence and molecular weight identity confirmed
- Endotoxin screened (<0.25 EU/mg)
- Lyophilized powder format
- Suitable for in vitro and preclinical research
- Batch-tested for consistency
- Research-grade manufacturing standards
- Professionally labeled and documented
Storage Recommendations
To maintain product stability and research integrity, CJC-1295 Without DAC should be:
- Stored at 2–8°C (lyophilized) or −20°C (reconstituted)
- Reconstituted in sterile or bacteriostatic water
- Aliquoted into single-use research volumes after reconstitution
- Protected from light and moisture
- Kept sealed until use
- Handled according to standard laboratory procedures
- Not subjected to repeated freeze-thaw cycles
Toxicology and Regulatory Information
- Evaluated in preclinical endocrinology and GH axis research models
- FDA Category 2 bulk substance (503A/503B compounding lists, September 2023; confirmed April 2026)
- Compounding by licensed 503A/503B pharmacies for human use prohibited
- Not evaluated by the FDA for safety or efficacy in any therapeutic application
- Supplied strictly as a Research Use Only (RUO) material under 21 CFR 312.2(b)(1)
Why Choose Summit Pep Labs?
At Summit Pep Labs, we are committed to supplying researchers with premium-quality compounds manufactured to rigorous analytical standards.
Why Researchers Choose Summit Pep Labs
- ≥99% RP-HPLC-verified purity
- LC-MS sequence and molecular weight identity confirmed — not purity alone
- Endotoxin screened per batch (<0.25 EU/mg)
- Batch consistency and traceability
- Professional labeling and packaging
- Research-grade manufacturing standards
- Secure shipping and quality assurance
- Commitment to reproducibility and reliability
Frequently Asked Questions
What is CJC-1295 Without DAC?
CJC-1295 Without DAC (Modified GRF 1-29) is a tetrasubstituted synthetic GHRH analog commonly referenced in scientific literature for pulsatile GH axis research, GHRH receptor signaling, and dual-pathway growth hormone secretagogue studies in laboratory and preclinical environments.
What is the difference between CJC-1295 Without DAC and CJC-1295 With DAC?
Both are 29-amino acid GHRH analogs with the same four stabilizing substitutions. The DAC variant includes an MPA chemical conjugate that binds covalently to serum albumin, extending half-life to approximately 6–8 days and producing sustained, tonic GH elevation. CJC-1295 Without DAC lacks this conjugate entirely, with a half-life of approximately 30 minutes producing discrete, pulsatile GH release — making the two variants appropriate for fundamentally different research endpoints.
What does Modified GRF (1-29) mean?
GRF (1-29) refers to the first 29 amino acids of Growth Releasing Factor. “Modified” designates the four amino acid substitutions that distinguish it from the native GRF (1-29) sequence (Sermorelin). Modified GRF (1-29), Mod GRF (1-29), and CJC-1295 Without DAC all refer to the same tetrasubstituted peptide reagent (PubChem CID 91976842).
Is CJC-1295 Without DAC approved for human use?
No. CJC-1295 Without DAC is not approved by the FDA for human or veterinary use. It is FDA Category 2 on the 503A/503B bulk substances compounding list and is supplied exclusively for research purposes.
What purity does Summit Pep Labs provide?
Each batch is tested and verified to contain ≥99% purity by RP-HPLC, with LC-MS identity confirmation and endotoxin screening per batch.
How is CJC-1295 Without DAC supplied?
CJC-1295 Without DAC is supplied as a lyophilized powder and packaged according to professional research standards.
How should CJC-1295 Without DAC be stored?
Lyophilized material should be stored at 2–8°C, protected from light and moisture. Once reconstituted in sterile or bacteriostatic water, store at −20°C in single-use aliquots and avoid repeated freeze-thaw cycles.
References
- Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792–4797. PMID: 16682504
- Bowers CY et al. Endocrinology. 1999;141:4554. PMID: 10372741
- Alba M et al. Am J Physiol Endocrinol Metab. 2006;291:E1290
- Raun K et al. Eur J Endocrinol. 1998;139:552–561. PMID: 9849822
- PubChem CID 91976842 — CJC-1295 Without DAC
- FDA Bulk Drug Substances Category 2 List — CJC-1295. FDA.gov. September 2023; April 2026
- National Center for Biotechnology Information (NCBI)
- U.S. Food and Drug Administration (FDA)
Research Use Only Disclaimer
For Research Use Only (RUO).
This product is intended strictly for laboratory and scientific research purposes. It is not intended for human consumption, veterinary use, cosmetic applications, therapeutic use, or diagnostic purposes.
By purchasing this product, customers acknowledge that they are qualified researchers and agree to use these materials in accordance with all applicable laws and regulations.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
There are no reviews yet.